$MRK (Merck & Co. Inc.)

$MRK {{ '2017-07-28T15:26:51+0000' | timeago}} • Announcement

Pharma giant $MRK reported better-than-expected sales due to strong demand from its cancer drug KEYTRUDA. Sales for KEYTRUDA tripled to $881MM vs. $314MM in 2Q16. Drugmarker also disclosed that cyber-attack (June 27) had a dent on its operations. Magnitude of the disruption is yet to be ascertained, as $MRK tries to restore from the attack.

$MRK {{ '2017-12-11T14:15:30+0000' | timeago}} • Announcement

Merck said today that the FDA has given consent to review a supplemental Biologics License Application (sBLA) for KEYTRUDA for the treatment of relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL), a type of non-Hodgkin lymphoma. FDA has granted $MRK Priority Review status and expected to complete evaluation by April 3, 2018.

$MRK {{ '2017-11-30T15:09:55+0000' | timeago}} • Announcement

Merck has received FDA approval for ISENTRESS (raltegravir) to treat neonates who are affected by HIV-1. With this approval, newborns right from birth to four weeks (weighing at least 2 kg) can be treated with $MRK’s raltegravir. The drug is not recommended for pre-term newborns/infants weighing less than 2 kg, due to lack of clinical trials data.

$MRK {{ '2017-11-28T20:32:10+0000' | timeago}} • Announcement

Merck's Board has increased the quarterly dividend by $0.01 to $0.48 per share vs. $0.47 paid last quarter. Dividend will be paid on Jan. 8, 2018 with cut off set at Dec. 15, 2017. In addition, $MRK's Board has also authorized $10Bil of treasury stock purchase without setting any deadlines.

$MRK {{ '2017-11-13T18:11:07+0000' | timeago}} • Announcement

$MRK announced that it has received positive opinion from Committee for Medicinal Products for Human Use (CHMP) for its antiviral drug PREVYMIS (letermovir). The drug helps to prevent cytomegalovirus (CMV) infections and disease in adults previously exposed to this virus who have received an allogeneic hematopoietic stem cell transplant.

$MRK {{ '2017-11-03T20:24:16+0000' | timeago}} • Webcast

In addition to oncology and animal health domains, $MRK is prioritizing its investments on certain vaccines and HIV, which is believed to deliver long-term growth. Sales of cancer drug KEYTRUDA eclipsed $1Bil for the first time in 3Q, which makes it the 2nd largest product in the Merck’s portfolio. 55% of its sales come from lung cancer in the US.

$MRK {{ '2017-10-27T18:19:48+0000' | timeago}} • Announcement

$MRK's blockbuster cancer drug Keytruda sales nearly tripled touching $1.05Bil vs. 3Q16 and Hepatitis C drug Zepatier sales jumped 185% to $468MM. Due to pressure from generic drugs, cholesterol drugs Zetia and Vytorin sales halved to a combined $462MM. Veterinary medicines sales increased 15% to $1Bil.

$MRK {{ '2017-10-27T17:17:47+0000' | timeago}} • Announcement

$MRK reported a loss of $56MM in 3Q, primarily due to a $2.35Bil charge for a new partnership with AstraZeneca to market cancer drugs. The company also added that the cyberattack in June impacted sales by $135MM. Despite 2% drop in 3Q sales, $MRK has raised its FY17 outlook with non-GAAP EPS expected to be $3.91-3.97 and sales between $40-40.5Bil.

$MRK {{ '2017-10-27T13:15:12+0000' | timeago}} • Infographic

$MRK Merck Earnings AlphaGraphic: Q3 2017 Highlights

$MYL {{ '2017-10-02T17:33:18+0000' | timeago}} • Announcement

$MYL announced the U.S. launch of Caspofungin Acetate for Injection, one of the first generic version of $MRK's Cancidas. $MYL received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for this antifungal which has multiple indications.

$A {{ '2017-09-22T21:43:23+0000' | timeago}} • Announcement

$A said its Dako PD-L1 IHC 22C3 pharmDx assay has an expanded label approved by the US FDA to aid in identifying gastric or GEJ adenocarcinoma patients for treatment with KEYTRUDA, an anti-PD-1 therapy manufactured by $MRK. These approvals mean these patients have the possibility of receiving a targeted anti-PD-L1 immunotherapy.

$MRK {{ '2017-09-11T17:08:33+0000' | timeago}} • Announcement

$MRK announced that Keytruda is the only programmed death (PD-1) drug with data to show it can improve overall survival rate in the second-line bladder cancer. Phase 3 results show that patients whose disease had progressed following platinum chemo treatment, Keytruda demonstrated an OS advantage vs. chemo with median follow-up of 22.5 months.

$MRK {{ '2017-08-29T14:59:23+0000' | timeago}} • Announcement

$MRK and Oxford University's Clinical Trial Service Unit announced the REVEAL study results of anacetrapib, the company's investigational cholesteryl ester transfer protein (CETP) inhibitor. Anacetrapib reduced the risk of major coronary events by 9% relative to placebo. $MRK is reviewing the results with external experts for filing NDA with FDA.

$MRK {{ '2017-08-18T15:18:52+0000' | timeago}} • Announcement

Lynparza, which is developed and marketed by AstraZeneca and $MRK, announced that it got approval for a two-tablet regimen, regardless of whether patients test positive for BRCA genetic mutations associated with high risk for the cancer. This helps Lynparza to compete with Tesaro’s Zejula and Clovis Oncology's Rubraca.

$MRK {{ '2017-08-18T13:37:46+0000' | timeago}} • Announcement

Lynparza has received FDA approval to include the drug in ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy. Lynparza (olaparib) claims to be the world's first poly (ADP-ribose) polymerase [PARP] inhibitor. The drug is jointly developed and sold by AstraZeneca and $MRK.

$MRK {{ '2017-07-28T15:52:14+0000' | timeago}} • Announcement

Pharma segment, $MRK's only reportable segment and money-spinner, rose modestly to $8.76Bil. Growth was mainly due to new product launches offset by generic drug launches from competition and lower diabetes drug sales. Merck also narrowed and raised its 2017 revenue outlook to $39.4-40.4Bil, but reduced its 2017 GAAP EPS forecast to $1.60-1.72.

$MRK {{ '2017-07-28T15:26:51+0000' | timeago}} • Announcement

Pharma giant $MRK reported better-than-expected sales due to strong demand from its cancer drug KEYTRUDA. Sales for KEYTRUDA tripled to $881MM vs. $314MM in 2Q16. Drugmarker also disclosed that cyber-attack (June 27) had a dent on its operations. Magnitude of the disruption is yet to be ascertained, as $MRK tries to restore from the attack.

$MRK {{ '2017-07-28T13:05:50+0000' | timeago}} • Infographic

$MRK Merck Earnings AlphaGraphic: Q2 2017 Highlights

$MRK {{ '2017-07-26T13:49:00+0000' | timeago}} • Announcement

$MRK's BoD declared a quarterly dividend of $0.47 per share of its common stock for 4Q17. The dividend will be paid on Oct. 6, 2017 to shareholders of record at the close of business on Sept. 15, 2017.

$MRK {{ '2017-07-25T17:08:10+0000' | timeago}} • Announcement

$MRK announced the presentation of results from the Drive-Ahead study, the second of two pivotal Phase 3 clinical trials evaluating the efficacy and safety of doravirine, the company's investigational, non-nucleoside reverse transcriptase inhibitor (NNRTI), for the treatment of HIV-1 infection.

$MRK {{ '2017-07-25T11:50:57+0000' | timeago}} • Announcement

$MRK said that its anti-programmed cell death protein 1 (PD1) drug Keytruda (pembrolizumab) failed to meet the primary endpoint in the Phase III KEYNOTE-040 trial for previously treated recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). When compared with standard treatment, Keytruda failed to improve the overall survival rate.

Recent Transcripts

ONVO (Organovo Holdings, Inc.)
Thursday, November 9 2017 - 10:00pm
TRXC (TransEnterix, Inc.)
Thursday, November 9 2017 - 9:30pm
ENDP (Endo International plc)
Thursday, November 9 2017 - 9:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 1:30pm
TARO (Taro Pharmaceutical Industries Ltd.)
Wednesday, November 8 2017 - 1:00pm
NKTR (Nektar Therapeutics)
Tuesday, November 7 2017 - 10:00pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, November 7 2017 - 1:00pm
TXMD (TherapeuticsMD, Inc.)
Monday, November 6 2017 - 1:00pm
ZTS (Zoetis Inc.)
Thursday, November 2 2017 - 12:30pm
SYN (Synthetic Biologics Inc.)
Wednesday, November 1 2017 - 8:30pm
MRK (Merck & Co. Inc.)
Friday, October 27 2017 - 12:00pm
SGEN (Seattle Genetics, Inc.)
Thursday, October 26 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, October 26 2017 - 2:30pm
MDCO (The Medicines Company)
Wednesday, October 25 2017 - 12:30pm
ILMN (Illumina Inc.)
Tuesday, October 24 2017 - 9:00pm
PG (The Procter & Gamble Company)
Friday, October 20 2017 - 12:30pm
PTN (Palatin Technologies Inc.)
Monday, September 25 2017 - 3:00pm
ONVO (Organovo Holdings, Inc.)
Wednesday, August 9 2017 - 9:00pm
MDCO (The Medicines Company)
Wednesday, August 9 2017 - 12:30pm
NKTR (Nektar Therapeutics)
Tuesday, August 8 2017 - 9:00pm

AlphaGraphics you may like